Analyst Note| Damien Conover, CFA |
We are raising our Dr. Reddy's fair value estimate to $49 after analyzing the positive trends impacting the firm. We now project high-single-digit revenue growth over our forecast period. The company has made a few acquisitions to replenish its portfolio over the past couple of years, including its 2020 acquisition of certain segments of Wockhardt’s generic business, consisting of roughly 62 brands across multiple therapies. These investments look to have a positive effect on the firm's growth potential.